Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Raises Safety, Efficacy Concerns About Dendreon’s Cancer Vaccine Provenge

This article was originally published in The Pink Sheet Daily

Executive Summary

Advisory committee will discuss cerebrovascular accident as a safety signal for Provenge, as well as the biologic’s failure to meet primary efficacy endpoints.

You may also be interested in...



Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine

Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.

Advisory Committee Votes Favorably On Dendreon’s Prostate Cancer Vaccine

Though questions remain, majority of members find Provenge has “substantial evidence” of efficacy.

Sanofi Gains Therapeutic Cancer Vaccine TroVax In Deal With Oxford BioMedica

Announcement of the $690 million deal comes one day ahead of an advisory committee meeting for Provenge, the first therapeutic cancer vaccine to reach FDA.

Related Content

Topics

UsernamePublicRestriction

Register

PS065822

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel